AbbVie Revenue 2010-2023 | ABBV

AbbVie annual/quarterly revenue history and growth rate from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • AbbVie revenue for the quarter ending December 31, 2023 was $14.301B, a 5.42% decline year-over-year.
  • AbbVie revenue for the twelve months ending December 31, 2023 was $54.318B, a 6.44% decline year-over-year.
  • AbbVie annual revenue for 2023 was $54.318B, a 6.44% decline from 2022.
  • AbbVie annual revenue for 2022 was $58.054B, a 3.3% increase from 2021.
  • AbbVie annual revenue for 2021 was $56.197B, a 22.69% increase from 2020.
AbbVie Annual Revenue
(Millions of US $)
2023 $54,318
2022 $58,054
2021 $56,197
2020 $45,804
2019 $33,266
2018 $32,753
2017 $28,216
2016 $25,638
2015 $22,859
2014 $19,960
2013 $18,790
2012 $18,380
2011 $17,444
2010 $15,638
2009 $14,214
AbbVie Quarterly Revenue
(Millions of US $)
2023-12-31 $14,301
2023-09-30 $13,927
2023-06-30 $13,865
2023-03-31 $12,225
2022-12-31 $15,121
2022-09-30 $14,812
2022-06-30 $14,583
2022-03-31 $13,538
2021-12-31 $14,886
2021-09-30 $14,342
2021-06-30 $13,959
2021-03-31 $13,010
2020-12-31 $13,858
2020-09-30 $12,902
2020-06-30 $10,425
2020-03-31 $8,619
2019-12-31 $8,704
2019-09-30 $8,479
2019-06-30 $8,255
2019-03-31 $7,828
2018-12-31 $8,305
2018-09-30 $8,236
2018-06-30 $8,278
2018-03-31 $7,934
2017-12-31 $7,739
2017-09-30 $6,995
2017-06-30 $6,944
2017-03-31 $6,538
2016-12-31 $6,796
2016-09-30 $6,432
2016-06-30 $6,452
2016-03-31 $5,958
2015-12-31 $6,400
2015-09-30 $5,944
2015-06-30 $5,475
2015-03-31 $5,040
2014-12-31 $5,452
2014-09-30 $5,019
2014-06-30 $4,926
2014-03-31 $4,563
2013-12-31 $5,111
2013-09-30 $4,658
2013-06-30 $4,692
2013-03-31 $4,329
2012-12-31 $5,206
2012-09-30 $4,508
2012-06-30 $4,493
2012-03-31 $4,173
2011-12-31 $4,864
2011-09-30 $4,409
2011-06-30 $4,274
2011-03-31 $3,897
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $287.341B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $714.182B 118.93
Novo Nordisk (NVO) Denmark $558.743B 46.03
Johnson & Johnson (JNJ) United States $355.491B 14.14
Merck (MRK) United States $318.503B 83.83
AstraZeneca (AZN) United Kingdom $213.711B 18.94
Novartis AG (NVS) Switzerland $198.225B 13.73
Pfizer (PFE) United States $146.433B 14.13
Sanofi (SNY) $116.185B 10.46
Innoviva (INVA) United States $0.925B 6.53